Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 29Neoplasms 14Breast Neoplasms 8Fallopian Tube Neoplasms 7Prostatic Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Melanoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Diseases 1Pancreatic Neoplasms 1Ovarian Diseases 1Osteosarcoma 1Neuroblastoma 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma 1Lung Neoplasms 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × niraparib × Clear all
NCT03221400 2022-02-17

PEN-866 in Patients With Advanced Solid Malignancies

Tarveda Therapeutics

Phase 1/2 Unknown
340 enrolled
GastrointestinalThoracic

Anus Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡